We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Carlisle Companies
CSL
$14.8B
| $3.1M | 0.01% |
13,000
-182,000
| -93% | -$45.3M |
|
|
RDNW
852
RideNow Group
RDNW
$264M
| $3.09M | 0.01% |
+210,000
| New | +$4.11M |
|
853
Saia
SAIA
$9.61B
| $3.06M | 0.01% |
16,277
-5,000
| -23% | -$1M |
|
|
IMGO
854
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $3.01M | 0.01% |
225,000
-50,000
| -18% | -$794K |
|
855
W.R. Berkley
WRB
$26.8B
| $2.94M | 0.01% |
64,725
-150,900
| -70% | -$6.86M |
|
|
TMAC
856
DELISTED
The Music Acquisition Corporation
TMAC
| $2.94M | 0.01% |
300,000
| – | – |
|
857
Campbell Soup
CPB
$6.67B
| $2.91M | 0.01% |
60,546
-6,100
| -9% | -$287K |
|
|
TELL
858
DELISTED
Tellurian Inc.
TELL
| $2.83M | 0.01% |
950,000
-1,650,000
| -63% | -$7.62M |
|
859
COPT Defense Properties
CDP
$4.26B
| $2.82M | 0.01% |
107,559
-126,975
| -54% | -$3.43M |
|
860
Cabaletta Bio
CABA
$439M
| $2.69M | 0.01% |
2,541,645
| – | – |
|
861
Suncor Energy
SU
$77.9B
| $2.63M | 0.01% |
75,000
-110,000
| -59% | -$4M |
|
|
KDNY
862
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.62M | 0.01% |
+150,000
| New | +$2.35M |
|
|
AQUA
863
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
| $2.6M | 0.01% |
80,000
+65,000
| +433% | +$2.47M |
|
864
ProQR Therapeutics
PRQR
$241M
| $2.57M | 0.01% |
3,300,000
| – | – |
|
|
OTLY
865
Oatly Group
OTLY
$468M
| $2.56M | 0.01% |
+37,000
| New | +$2.89M |
|
|
JNPR
866
DELISTED
Juniper Networks
JNPR
| $2.46M | 0.01% |
86,500
-253,100
| -75% | -$7.98M |
|
867
Forum Energy Technologies
FET
$791M
| $2.45M | 0.01% |
125,000
+89,934
| +256% | +$2M |
|
868
PTC Therapeutics
PTCT
$5.68B
| $2.4M | 0.01% |
60,000
-70,000
| -54% | -$2.45M |
|
869
Navigator Holdings
NVGS
$1.35B
| $2.26M | 0.01% |
+200,000
| New | +$2.59M |
|
|
ISEE
870
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.12M | ﹤0.01% |
220,000
-280,000
| -56% | -$3.51M |
|
871
Amcor
AMCR
$21.3B
| $2.11M | ﹤0.01% |
34,018
-243,120
| -88% | -$15M |
|
872
AerCap
AER
$24.2B
| $2.09M | ﹤0.01% |
51,030
-25,100
| -33% | -$1.16M |
|
873
Immunic
IMUX
$192M
| $2.08M | ﹤0.01% |
+60,090
| New | +$3.85M |
|
874
Rezolute
RZLT
$473M
| $2.04M | ﹤0.01% |
+631,690
| New | +$2.1M |
|
875
Astec Industries
ASTE
$1.21B
| $2.04M | ﹤0.01% |
50,000
-150,000
| -75% | -$6.38M |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.